Name:	lxrx_SanofiCommercializationCostsFundedByLexiconPercentage
Namespace Prefix:	lxrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the maximum amount that Lexicon will fund of the planned type 2 diabetes development costs.

No definition available.

Name:	lxrx_SanofiCommercializationCostsFundedbyLexiconMaximumAmount
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential development and regulatory milestone payments under the agreement.

No definition available.

Name:	lxrx_SanofiDevelopmentandRegulatoryMilestonePayments
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

No definition available.

Name:	lxrx_SanofiMaximumRoyaltyPercentage
Namespace Prefix:	lxrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the potential sales milestones payments under the agreement.

No definition available.

Name:	lxrx_SanofiSalesMilestonePayments
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

No definition available.

Name:	lxrx_SanofiUpfrontPayment
Namespace Prefix:	lxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Subsequent Event

No definition available.